IRVINE, Calif., Sept. 27, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against The Advisory Board Company (“Advisory Board” or the “Company”) (Nasdaq:ABCO). Investors who purchased or otherwise acquired shares from January 21, 2015 through February 23, 2016, inclusive (the “Class Period”), are encouraged to contact the Firm before October 2, 2017, the lead plaintiff motion deadline.
If you purchased shares of Advisory Board during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
The Complaint alleges that throughout the Class Period, Advisory Board made materially false and/or misleading statements, and/or failed to disclose, that there were severe integration problems associated with its acquisition of Royall and, as a consequence of these integration problems, the Company had no basis to increase the revenue guidance for Royall during the Class Period. When this information reached the public, Advisory Board’s stock price decreased materially, which harmed investors according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Samsung Electronics Shares Jump on HBM4 Mass Production Report 



